Company intelligence / Profile preview

Osanni Bio

San Carlos / San Francisco Bay Area / San Francisco, California, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Osanni Bio develops novel therapies to prevent and reverse blindness caused by retinal diseases. Their approach leverages creativity in science through design thinking, focusing on multi-factorial causes of retinal disease. They are building a pipeline of intraocular therapeutics using sterile liquid formulations and sustained-release biodegradable dosage forms. No published clinical results yet; programs appear to be preclinical or early-stage development

Therapeutic areas: Ophthalmology
Modalities: Sterile liquids and sustained-release biodegradable dosage forms for intraocular (eye) drug delivery
Industry: Biotech

Beyond the preview

Go deeper on Osanni Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Osanni Bio.

Explore the full profile